be reached based on lowquality evidence across the critical outcomes and transparently rates the strength of the recommendation as well as the quality of the evidence supporting the recommendation Perioperative management of rituximab has been a challenge given the long dosing interval of 6 months and the recognized risk of severe infection linked to its use As previously, the recommendations that form this guideline are not treatment mandates. These recommendations will provide the backbone